EUVIMEDEUVIMED entdecken
Crossref

Using Nomograms to Predict Patient Tolerance to High‐Dose Cisplatin During Concurrent Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer

Ming-Yu Lien, Chia-Yu Chen iD, Ching-Yun Hsieh, Ming-Hsui Tsai, Chun-Hung Hua, Wen-Hui Chung, Ti-Hao Wang iD

Head & Neck · 2025

DOI: 10.1002/hed.28164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Ming-Yu Lien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung City, Taiwan. Hauptthemen laut MEDLINE: Cisplatin, Nomograms, Head and Neck Neoplasms, Chemoradiotherapy. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concurrent chemoradiotherapy (CCRT) with high‐dose cisplatin is the standard treatment for locally advanced head and neck cancer (LA‐HNC). However, some patients experience underdosing or severe side effects due to intolerance. That is, identifying patients who can tolerate high‐dose cisplatin remains challenging.

Methods

This study aims to develop a prediction nomogram to identify patients tolerating high cumulative cisplatin dose (CCD ≥ 200 mg/m 2 ) during CCRT. The collected data of 1020 patients who received cisplatin‐based definitive CCRT between 2010 and 2019 in a Taiwanese medical center were retrospectively reviewed.

Results

A prediction model was developed using stepwise multivariable logistic regression and evaluated for accuracy. A nomogram was created to predict the likelihood of completing a CCD ≥ 200 mg/m 2 , and its performance was assessed using various measures. The higher CCD group had better‐experienced status and median body mass index than the lower CCD group ( p < 0.001 for both comparisons). Univariate analysis identified several risk factors for high‐dose cisplatin intolerance, including old age, tumor site, the nasopharynx, stage IV disease, Charlson Comorbidity Index (CCI) ≥ 3, and weekly cisplatin ( p < 0.001 for all). Multivariate logistic regression analysis revealed that age, tumor site, stage IV disease, and hemoglobin level strongly predicted high‐dose cisplatin intolerance. The nomogram showed good predictive accuracy with a Brier score of 0.18, C‐index of 0.71, calibration curve slope of 0.95, and intercept of 0.2. Similar values were observed in the non‐nasopharyngeal carcinoma subgroup.

Conclusions

Our nomogram model identified patients who can tolerate higher cisplatin doses, showing predictive accuracy after internal validation. Developed using pretreatment characteristics like age, clinical stage, tumor size, and hemoglobin level, it predicts tolerability for CCD ≥ 200 mg/m 2 . This method helps select patients for high‐dose cisplatin, enabling confident prescription of three‐weekly or weekly dosing to improve survival outcomes. Further prospective research is needed for a comprehensive nomogram.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinNomogramsHead and Neck NeoplasmsChemoradiotherapyAntineoplastic AgentsSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTaiwan

Stichwörter der Autor:innen

concurrent chemoradiotherapycumulative cisplatin dosehead and neck cancerinduction chemotherapynomogram

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung City, Taiwan.
  • Department of Medicine, China Medical University, Taichung City, Taiwan.
  • Department of Otolaryngology, China Medical University Hospital, Taichung City, Taiwan.
  • Department of Otorhinolaryngology, China Medical University Hospital, Taichung City, Taiwan.
  • China Medical University Hospital, Taichung City, Taiwan.

ORCID-Profile: Chia-Yu Chen, Ti-Hao Wang

Zitieren

APA

Lien, M. Y., Chen, C. Y., Hsieh, C. Y., Tsai, M. H., Hua, C. H., Chung, W. H., & Wang, T. H. (2025). Using Nomograms to Predict Patient Tolerance to High‐Dose Cisplatin During Concurrent Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer. Head & Neck. https://doi.org/10.1002/hed.28164

Vancouver

Lien MY, Chen CY, Hsieh CY, Tsai MH, Hua CH, Chung WH, et al. Using Nomograms to Predict Patient Tolerance to High‐Dose Cisplatin During Concurrent Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer. Head & Neck. 2025. doi:10.1002/hed.28164

BibTeX
@article{Lien2025,
  author = {Lien, Ming-Yu and Chen, Chia-Yu and Hsieh, Ching-Yun and Tsai, Ming-Hsui and Hua, Chun-Hung and Chung, Wen-Hui and Wang, Ti-Hao},
  title = {Using Nomograms to Predict Patient Tolerance to High‐Dose Cisplatin During Concurrent Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.28164}
}
Kostenlos starten →